Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,303 total articles
Labcorp Holdings Inc. (NYSE: LH) SVP and Chief Accounting Officer Peter J. Wilkinson sold 1,633 shares on March 27, 2026, for $267.05 per share, generating $436,092. The sale was executed under a Rule 10b5-1 plan. The company recently reported fourth-quarter 2025 earnings that beat EPS expectations but missed revenue forecasts, and announced an exp…
Labcorp Holdings Inc. Executive Vice President of Operations Jonathan C. Meltzer sold 839 shares on March 27, 2026, for $267.05 each, generating $224,054. The day prior he received 2,388 shares tied to a performance award, and 711 shares were withheld for taxes at $268.38. These filings were disclosed on a Form 4 with the SEC. The company also repo…
Chemed Corp President and CEO Kevin J. McNamara sold 1,500 shares of company stock on March 27, 2026, for about $554,055. The transaction occurred as the stock traded near its 52-week low and after the company reported fourth-quarter 2025 results that missed analyst expectations, prompting an RBC Capital downgrade driven by concerns over Roto-Roote…
Japan Post Holdings Co., Ltd. sold 14,899 shares of Aflac Inc. on March 26, 2026, in two separate trades totaling $1.6 million. The sales came at prices between $107.04 and $108.29 per share. Aflac's most recent quarter showed a revenue beat and an EPS miss, and at current prices the stock is assessed as slightly overvalued by InvestingPro analysis…
AAR Corp (NYSE:AIR) Chairman, President and CEO John McClain Holmes III executed option exercises that produced 86,225 shares and then sold those shares for approximately $9.5 million across March 26 and 27. The exercised options were at prices between $37.66 and $37.74, and the sales transacted at prices ranging from $107.6039 to $112.4135. Follow…
GlobalFoundries Chief Legal Officer Azar Samak L sold 500 ordinary shares on March 26, 2026, for $22,995 under a Rule 10b5-1 plan. The transaction comes as the company navigates a Mubadala-led secondary offering, patent infringement litigation against Tower Semiconductor, and a substantial share sale by a Mubadala unit that was reportedly oversubsc…
Lemonade, Inc. director Maria Angelidis-Smith purchased a total of $485,478 in common stock on March 10, 2026, split between direct and trust transactions. The moves were disclosed in a Form 4/A filing with the Securities and Exchange Commission. The company recently reported fourth-quarter 2025 results that beat analyst expectations on both earnin…
Jorey Chernett, a 10% holder of Neuronetics, purchased 500,000 shares on March 27, 2026, paying between $1.28 and $1.41 per share for a total outlay of $675,000. The trade leaves Chernett with 9,393,276 shares. The transaction comes alongside Neuronetics' fourth-quarter 2025 results, which showed revenue above forecasts but an EPS shortfall, and a …
Horace Mann Educators Corp Chief Marketing Officer Steven R. Chauby bought 180 shares on March 26, 2026, spending $7,632 at $42.40 per share. The purchase leaves Chauby with 4,643.023 shares directly and 500 shares indirectly through a domestic partner. The $1.7 billion insurance company reported Q4 2025 results that exceeded analysts' expectations…
IperionX Ltd (NASDAQ: IPX) President Toby Edgcumbe Symonds purchased 11,000 American Depository Shares on March 27, 2026, for $23.8684 apiece, totaling $262,552. The trade comes while the stock trades near $23.15 and has fallen 53% over six months. Recent analyst initiations from BTIG and William Blair accompany the transaction as IperionX starts c…
Rubin Shmuel, President and CEO of LightPath Technologies INC (NASDAQ: LPTH), purchased 180 shares of Class A common stock on March 27, 2026, spending roughly $1,745. The transaction comes amid a quarter that produced a revenue beat driven by defense and security demand, even as reported EPS fell short of forecasts and one analyst raised their pric…
Director Tripeny R Tony acquired 4,187 American Depositary Shares of IPERIONX Ltd on March 27, 2026, for $23.7554 per share, a transaction valued at $99,463. The purchase leaves the director with direct holdings across ADS, ordinary shares, and RSUs while the company moves into commercial production and receives new analyst coverage.
IperionX Ltd director Todd Hannigan acquired 225,225 ordinary shares on March 27, 2026, paying $3.20 per share for a total outlay of approximately $721,000. The purchase comes while the stock has fallen sharply over recent months even as the company begins commercial production at its Virginia facility and attracts positive analyst initiation.
Director George Jeffrey P. bought 5,592 shares of LENZ Therapeutics on March 27, 2026, paying a weighted average of $8.92 per share for a total of $49,890. The trade followed a 24% one-week decline that left the stock trading near a 52-week low. LENZ recently reported Q4 2025 results that included a solid cash position and early revenue from its pr…
Lenz Therapeutics CEO Evert B. Schimmelpennink bought 28,089 shares on March 27, 2026, spending about $251,410. The insider purchase comes while the stock trades near a 52-week low and after the company reported initial revenue from its presbyopia treatment VIZZ alongside a quarter marked by elevated operating costs and a net loss.
Daniel R. Chevallard, chief financial officer of LENZ Therapeutics, acquired 7,500 shares on March 27, 2026, for $8.57 per share, a transaction valued at $64,275. The purchase, disclosed on a Form 4 filing with the SEC, brings his direct ownership to 12,886 shares. The insider buy occurs as LENZ shares trade close to a 52-week low and after the com…
IperionX Ltd Chief Executive Anastasios Arima disclosed purchases on March 27, 2026 totaling $1.79 million. The transactions, reported on an SEC Form 4, included 467,000 Ordinary Shares and 12,800 American Depository Shares. The company recently began commercial production at its Virginia facility and is the subject of fresh analyst coverage and pr…
Nicholas D. Varischetti, a director of Farmers National Banc Corp (FMNB), purchased 2,000 shares on March 26, 2026, for $12.90 a share, a transaction valued at $25,800. The purchase price was near the prevailing market price of $12.88. InvestingPro data cited alongside the transaction shows the stock trading at a P/E ratio of 8.9 and yielding 5.28%…
Eric P. Lefkofsky, CEO and Chairman of Tempus AI, sold 151,520 shares of Class A common stock on March 26, 2026, in transactions conducted through entities he manages. The sales totaled $7,711,150 and were carried out at prices between $45.78 and $47.42. Despite the disposals, Lefkofsky still holds substantial positions across multiple entities and…
Gen IV Investment Opportunities and related entities sold 2,369,769 shares of Battalion Oil Corp (NASDAQ: BATL) on March 25, 2026, for $5.8206 per share, generating proceeds of $13,793,477. The filing shows the reporting owners no longer hold any Battalion shares. The transaction comes as the stock has exhibited extreme short-term swings and the co…
Glaukos NASDAQ:GKOS Senior Vice President and Chief Financial Officer Alex R. Thurman sold 2,511 shares on March 25, 2026, for $106.46 per share, totaling $267,321, under a Rule 10b5-1 trading plan. The transaction left Thurman with 41,967 shares held directly, including 5,230 unvested restricted stock units. On the same date he recorded acquisitio…
Dave & Buster's Entertainment Inc CEO Tarun Lal executed two purchases totaling $69,690 for the company’s common stock in September and October 2025. The transactions — 2,500 shares at $20.52 on September 18 and 1,000 shares at $18.39 on October 21 — leave Lal with 11,560 shares directly held. The stock has since fallen to $9.81, close to its 52-we…
Anaptysbio President and CEO Daniel Faga sold 16,571 shares on March 27, 2026, to meet tax withholding obligations tied to recently vested performance-based restricted stock units. The company is moving ahead with a planned April 20, 2026 spinoff of First Tracks Biotherapeutics, which raised $80 million in a private placement, and its board has app…
Director Juan Jose Chacon Quiros sold 3,575 shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) on March 25, 2026, in a transaction totaling approximately $214,768. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Separately, Establishment Labs reported fourth-quarter 2025 results that exceeded expectations, with an EPS of…
Adam Crystal, President of R&D at Tango Therapeutics (TNGX), sold 12,000 shares on March 25, 2026, realizing roughly $241,320, and simultaneously exercised options to acquire 12,000 shares at a $5.20 strike. The transactions were carried out under a Rule 10b5-1 plan adopted on October 27, 2025. Tango reported a net loss of $38.7 million in Q4 2025 …
